Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Registration of Children With CML and Treatment With Imatinib (CML-paed II)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Technische Universität Dresden.
Recruitment status was  Recruiting
Medical Academy of Wroclaw, Poland
University of Leiden, Netherlands
Nordic Society for Pediatric Hematology and Oncology
Uniuversity of Genua, Italy
Information provided by:
Technische Universität Dresden Identifier:
First received: March 8, 2007
Last updated: February 28, 2012
Last verified: February 2012

Newly diagnosed pediatric patients (age < 19 years) with bcr-abl-positive CML will be treated with imatinib. Serial monitoring of treatment response is performed in one month intervals during the first three months of treatment and in three months intervals thereafter. Patients with non-response, poor response (either molecular, cytogenetic, or hematologic non-/poor response) or progress of the disease while under imatinib treatment will stop imatinib and undergo stem cell transplantation. All responders to imatinib treatment with an HLA matched donor will undergo stem cell transplantation not later than 2 years after diagnosis.

Myeloid Leukemia, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol for Standardized Diagnostic Procedures, Registration, and Treatment Recommendations in Children and Adolescents With Philadelphia Chromosome-positive Chronic Myeloid Leukemia (CML)

Resource links provided by NLM:

Further study details as provided by Technische Universität Dresden:

Biospecimen Retention:   Samples With DNA

Bone Marrow and blood smears

Estimated Enrollment: 150
Study Start Date: March 2007
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Pts younger than 19 years with PH+ CML are recruited from primary care clinics


Inclusion Criteria:

  • Newly diagnosed Ph+ or bcr-abl-positive CML
  • Male and female patients aged 0 to 18 years
  • Written informed consent

Exclusion Criteria:

  • CML without bcr-abl rearrangement detectable by PCR
  • Pretreatment with Interferon alpha or any other cytostatic drug with the exception of hydroxyurea or anagrelide (Note: anagrelide is not approved in Germany for treatment of CML). However, these patients may be registered as observational patients.
  • Any other severe underlying disease beside CML.
  • Age > 18 years- Pregnant or lactating women
  • Subjects unlikely to comply with the requirements of the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00445822

Contact: Meinolf Suttorp, Prof. Dr. +49 351 458 ext 3522
Contact: Xenia Graehlert, Dr. +49 351 458 ext 5160

University Children's Hopsital, Technical University of Dresden, Fetscherstr. 74 Recruiting
Dresden, Saxonia, Germany, D-01307
Contact: Meinolf Suttorp, Prof. Dr.    +49 351 458 ext 3522   
Sponsors and Collaborators
Technische Universität Dresden
Medical Academy of Wroclaw, Poland
University of Leiden, Netherlands
Nordic Society for Pediatric Hematology and Oncology
Uniuversity of Genua, Italy
Principal Investigator: Meinolf Suttorp, Prof. Dr. University Children's Hospital, Dpt. Ped. Hemato-Oncology, Technical University of Dresden, Germany
  More Information


Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Dr. Meinolf Suttorp, Universitätskinderklinik Dresden Identifier: NCT00445822     History of Changes
Other Study ID Numbers: TUD-CML-paed 016, EudraCT: 2007-001339-69
Study First Received: March 8, 2007
Last Updated: February 28, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by Technische Universität Dresden:
Imatinib mesylate

Additional relevant MeSH terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms by Histologic Type processed this record on November 20, 2014